Calviri

$17.4M disclosed across 7 rounds · 2018–2024

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

KA

KaliVir Immunotherapeutics4 shared keywordsKaliVir Immunotherapeutics develops oncolytic viral immunotherapies for the treatment of advanced solid tumors, including its VET3-TGI candidate being evaluated in combination with checkpoint inhibitors. The company operates in the immuno-oncology and biotechnology sector.

AN

Anivive Lifesciences4 shared keywordsAnivive develops new medicines for companion animals, using software across the drug development process to accelerate the creation of treatments. It serves the animal health community, focusing on veterinary and pet health pharmaceuticals.

KY

Kyverna Therapeutics3 shared keywordsKyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset. The company conducts clinical trials for multiple autoimmune conditions globally.

TR

Triumvira Immunologics3 shared keywordsTriumvira develops TAC (T cell Antigen Coupler) technology that enables T cells to target and destroy tumor cells, applicable across liquid and solid cancers. The company is building a pipeline of TAC-T cell therapies using both autologous and allogeneic manufacturing approaches for cancers with high unmet need.

TO

Torigen Pharmaceuticals3 shared keywords

Companies competing with Calviri for the same Google search keywords, organic and paid, via search-intersection analysis.

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.